Unknown PHASE1 INTERVENTIONAL 1-arm NCT03383952

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.

Sponsor: Immune Cell, Inc.

Conditions B Cell Leukemia B Cell Lymphoma

Updated 6 times since 2018 Last updated: Dec 19, 2017 Started: Mar 1, 2017 Primary completion: Dec 31, 2020 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates B Cell Leukemia and B Cell Lymphoma and is currently ongoing. Immune Cell, Inc. leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE1
Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2018 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immune Cell, Inc.
Weifang People's Hospital

Data source: Immune Cell, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Weifang, China